Two companies have launched based on the biodosimeter technology license negotiated and finalized with The Ohio State University (OSU) Technology Commercialization Office. We are branding these companies within the CAPTURE Collective — one company is focused on the emergency response market and the second is focused on the personalized medicine market related to radiation treatment for oncology patients.
The terms of this license facilitate the splitting of the two patents into respective companies in order to optimize resource allocation and future exit valuation potential in the aggregate. The emergency response company is the fastest moving of the two companies. Combined, these two markets for this revolutionary biodosimetry technology represent a significant business opportunity for Ikove and our SUN Fund investors.